Aptose shareholders approve Hanmi go-private at C$2.41/share; FY net loss $25.5M

Aptose Biosciences Inc.

Shareholders approved acquisition by Hanmi at C$2.41/share (28% premium over 30-day VWAP of C$1.88).
84.87% of non-Hanmi shares voted for the arrangement; Alberta court issued final order; closing expected by end of April 2026.
FY2025 net loss $25.5M (flat vs $25.4M); cash $4.1M as of Dec 31, 2025; company notes insufficient cash to fund operations; relies on Hanmi advances.
TUS+VEN+AZA triplet in newly diagnosed AML showed 90% CR/CRh, 78% MRD negativity by central flow; no dose-limiting toxicities.
Hanmi provided over US$41M in debt facilities over past 18 months to support Aptose.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.